Skip to main content
TipRanks
Go Ultimate75% OFF

Avita Medical (RCEL) AI Stock Analysis

439 Followers
RCEL

Avita Medical

(NASDAQ:RCEL)

Select Model
Rating:60Neutral
Price Target:$16.50â–²(8.41% Upside)
Action:reiterated
Date:11/06/26

RCEL’s score is driven by strong technical momentum and a very favorable earnings-call outlook (raised revenue guidance, high expected gross margins, and a stated path to near-term cash-flow breakeven with improved liquidity). These positives are tempered by weaker financial fundamentals—negative equity, ongoing net losses, and continued negative operating/free cash flow—plus limited valuation support due to the negative P/E and no dividend.

Positive Factors
Revenue GrowthRepeatedly higher guidance and projected growth from about $35 million in 2022 indicate expanding commercial adoption of RECELL and related products. Sustained top-line growth can support operating leverage, broaden the installed customer base, and strengthen the company’s ability to fund expansion.
Negative Factors
Negative Equity and LeverageNegative equity reflects accumulated losses and leaves the company with limited balance-sheet flexibility relative to its debt burden. This can constrain investment choices and increase reliance on refinancing, additional borrowing, or equity issuance while profitability remains unproven.

Avita Medical Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down sales across countries and regions to reveal where Avita is gaining traction and where growth depends on local approvals, reimbursement, or market access. Geographic concentration can expose the company to regulatory shifts, currency swings, or supply-chain disruption, while diverse regional sales point to broader commercial resilience.

AU$0.00AU$5.00MAU$10.00MAU$15.00MAU$20.00MMar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Revenue is almost entirely U.S.-driven, with international markets contributing only noise—recent EU/UK/Japan blips haven’t meaningfully diversified the base. Management’s guidance and reimbursement wins hinge on normalization of ReCell utilization across ~200 core U.S. centers, so upside is execution- and payer-dependent; one remaining MAC and quarterly margin pressure from mix/reserves are key downside risks. The refinancing eases covenant risk, but durable growth requires sustained U.S. utilization recovery and successful commercialization of CoHiliX/PermeDerm.

Data provided by:The Fly

Avita Medical (RCEL) vs. SPDR S&P 500 ETF (SPY)

-100%0%100%200%300%400%RCEL+296.35%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$378.11M
Dividend Yield
―
Average Volume (3M)
432.07K
Price to Earnings (P/E)
-12.9
Beta (1Y)
1.71
Revenue Growth
16.96%
EPS Growth
34.83%
Country
US
Employees
226
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Avita Medical Business Overview & Revenue Model

Company Description

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harves...

How the Company Makes Money

Avita Medical primarily makes money by selling its RECELL System and associated single-use consumables used in each procedure (e.g., kits/components required to prepare the autologous skin cell suspension). Revenue is generated when hospitals, burn c...

Avita Medical Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-2.93%|Next Earnings Date:Feb 28, 2022
Earnings Call SentimentPositive

The call was strongly positive. Revenue growth accelerated, RECELL adoption expanded, Cohealyx grew, PermeaDerm produced favorable clinical and economic results, gross margin improved, cash use declined substantially, liquidity strengthened through the additional $10 million credit-facility draw, and full-year guidance was raised for the second consecutive quarter. The main challenges were flat international RECELL and PermeaDerm revenue, continued net losses, lower margins for newer products, ongoing hospital adoption reviews, and some uncertainty around seasonal Q3 volume; these issues were outweighed by the reported operating and financial improvements.

Positive Updates

Strong Third-Quarter Revenue Growth
Third-quarter revenue reached $26.1 million, up 53% year-over-year from $17.1 million and 20% from the second quarter. Revenue for the first nine months of 2026 was approximately $67.1 million.

Negative Updates

International RECELL Revenue Was Flat
International RECELL revenue was approximately $900,000, essentially flat with Q2, and remains a smaller contributor to total revenue.

Company Guidance

AVITA raised full-year 2026 revenue guidance to $92 million-$94 million from $86 million-$89 million, representing approximately 28%-31% growth over 2025, with $93 million at the midpoint, compared with approximately $35 million in 2022 and a compound annual growth rate of approximately 28% over four years; the guidance implies Q4 revenue of approximately $24.9 million-$26.9 million and approximately 30% growth for the full year over 2025, while the company remains on track to achieve cash flow breakeven in the fourth quarter. RECELL gross margin is currently expected to remain between 85% and 90% over the coming quarters. For 2027, management is not providing formal guidance but said it expects to grow at a rate that it has been growing, keep operating expenses flat, and does not see headcount going up significantly, with commissions having some variability as revenue goes up.

Avita Medical Financial Statement Overview

Summary

Operating trajectory is improving (TTM revenue ~$84.7M with ~12% growth, very strong ~82% gross margin, EBITDA slightly positive), but the financial foundation is still weak: net margin remains deeply negative (~-43%), stockholders’ equity is negative (~-$31M), and cash generation is still negative (TTM operating cash flow ~-$19.7M; free cash flow ~-$18.1M). Overall, improving operations are offset by balance-sheet and cash-burn risk.

Income Statement

47Neutral

Balance Sheet

24Negative

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Jun 2021
Income Statement
Total Revenue84.68M71.61M64.25M50.14M34.42M33.02M
Gross Profit69.75M58.82M55.16M42.36M28.38M26.92M
EBITDA-28.52M-41.23M-55.30M-33.54M-26.05M-24.07M
Net Income-36.12M-48.59M-61.84M-35.38M-26.66M-25.14M
Balance Sheet
Total Assets46.79M56.39M79.71M111.64M98.26M116.02M
Cash, Cash Equivalents and Short-Term Investments10.50M18.18M35.88M89.06M79.34M85.16M
Total Debt47.13M46.05M45.98M42.41M918.00K1.64M
Total Liabilities77.83M73.04M75.21M62.58M13.52M11.39M
Stockholders Equity-31.04M-16.65M4.50M49.06M84.74M104.62M
Cash Flow
Free Cash Flow-18.24M-32.93M-58.27M-39.46M-19.61M-18.52M
Operating Cash Flow-19.72M-31.20M-48.94M-38.01M-19.09M-18.04M
Investing Cash Flow7.83M12.45M37.36M1.61M-19.33M-50.21M
Financing Cash Flow6.96M14.94M3.51M40.37M900.00K64.06M

Avita Medical Technical Analysis

Technical Analysis SentimentNeutral
Last Price15.22

Price Trends

50DMA13.48Positive
100DMA10.08Positive
200DMA7.22Positive

Market Momentum

MACD0.79Positive
RSI50.29Neutral
STOCH23.86Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCEL, the sentiment is Neutral. The current price of 15.22 is below the 20-day moving average (MA) of 15.93, above the 50-day MA of 13.48, and above the 200-day MA of 7.22, indicating a neutral trend. The MACD of 0.79 indicates Positive momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 23.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RCEL.

Avita Medical Risk Analysis

Avita Medical disclosed 39 risk factors in its most recent earnings report. Avita Medical reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Tariffs and Changes in Trade Policy Could Adversely Affect Our Business, Financial Condition, and Results of OperationsQ4, 2025
2.Tariffs and Changes in Trade Policy Could Adversely Affect Our Business, Financial Condition, and Results of OperationsQ1, 2025
3.The Company's cash, cash equivalents and marketable securities could be adversely affected by bank failures or other events affecting financial institutions and could adversely affect our liquidity and financial performance.Q4, 2023

Avita Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RCEL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
BVSBVS66Neutral$881.37M12.3527.23%―3.87%623.68%
RCELRCEL60Neutral$478.22M-12.89146.38%―16.96%34.83%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SNWVSNWV47Neutral$15.57M5.90113.13%―-0.61%―
SRTSSRTS45Neutral$38.52M-2.41-38.65%―-53.33%-429.93%
TELATELA43Neutral$34.42M-1.05425.91%―1.46%15.79%
IARTIART40Underperform$1.09B84.361.24%―0.84%―

* Healthcare Sector Average

Performance Comparison

0%100%200%300%RCELIARTSNWVSRTSTELABVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RCEL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RCELAvita Medical Ltd15.2211.27285.32%
IARTIntegra Lifesciences13.982.8325.38%
SNWVSanuwave Health Inc.1.81-30.33-94.37%
SRTSSensus Healthcare, Inc.2.34-1.70-42.08%
TELATela Bio, Inc.0.76-0.32-29.54%
BVSBioventus, Inc.10.463.7455.65%

Avita Medical Corporate Events

Private Placements and FinancingRegulatory Filings and Compliance

Avita Medical Reports Warrant Exercise and Share Issuance

Neutral
Nov 2, 2026

On November 2, 2026, Avita Medical lodged filings with the ASX disclosing Perceptive Credit Holdings V, LP’s exercise of a warrant issued June 5, 2026, under a January 13, 2026 credit agreement. Perceptive exercised the warrant cashlessly on October...

Business Operations and Strategy

Avita Medical Expands PermeaDerm Global Distribution Agreement

Positive
Aug 11, 2026

On August 5, 2026, Avita Medical entered into a Global Amendment with Stedical Scientific that enhances its economic stake in PermeaDerm, raising its revenue share to 67% on sheet products and 80% on glove products, with potential adjustments if marg...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026